Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor

BACKGROUND: Dipeptidylpeptidase 4 (DPP4) inhibitors have clinical benefit in patients with type 2 diabetes mellitus by increasing levels of glucose-lowering incretin hormones, such as glucagon-like peptide -1 (GLP-1), a peptide with a short half life that is secreted for approximately 1 hour followi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Aiying, Dorso, Charles, Kopcho, Lisa, Locke, Gregory, Langish, Robert, Harstad, Eric, Shipkova, Petia, Marcinkeviciene, Jovita, Hamann, Lawrence, Kirby, Mark S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373380/
https://www.ncbi.nlm.nih.gov/pubmed/22475049
http://dx.doi.org/10.1186/1471-2210-12-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373380/
https://www.ncbi.nlm.nih.gov/pubmed/22475049
http://dx.doi.org/10.1186/1471-2210-12-2

Ejemplares similares